UK Markets open in 7 hrs 22 mins
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     
  • HANG SENG

    20,717.24
    +596.56 (+2.96%)
     
  • CRUDE OIL

    110.35
    +0.46 (+0.42%)
     
  • GOLD FUTURES

    1,845.10
    +3.90 (+0.21%)
     
  • DOW

    31,261.90
    +8.77 (+0.03%)
     
  • BTC-GBP

    23,540.50
    -128.54 (-0.54%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • Nasdaq

    11,354.62
    -33.88 (-0.30%)
     
  • ^FTAS

    4,083.84
    +44.90 (+1.11%)
     

Kinarus Shareholders Approve Reverse Takeover by Perfect Holding SA

·2-min read

Kinarus AG / Key word(s): Agreement/Financing
Kinarus Shareholders Approve Reverse Takeover by Perfect Holding SA
20.04.2022 / 06:45

MEDIA RELEASE (PDF)

Basel, Switzerland, April 20, 2022. Kinarus AG ('Kinarus') announced today that one important condition of the approval of the reverse takeover transaction by its shareholders has been fulfilled, with acceptance declarations received representing more than the required qualified majority of at least 66% of the shareholding of Kinarus.

The two other main conditions are (1) the approval of the transaction by the shareholders of Perfect Holding, scheduled to be voted on at Perfect Holding's shareholders meeting of May 2, 2022, and (2) the approval by SIX Swiss Exchange of the listing of the new shares of Perfect Holding to be issued to the shareholders of Kinarus. An application has been filed with SIX Swiss Exchange together with a draft prospectus.

This follows on the March 30, 2022, announcement of the signing of a transaction agreement contemplating the acquisition by Perfect Holding of Kinarus by way of a share exchange. The issuance of new shares in Perfect Holding to the shareholders of Kinarus will be made against contribution, in kind, of the shares in Kinarus in a capital increase of Perfect Holding.

  • Shareholders representing more than two-thirds of Kinarus shares agree to tender their shares for shares of Perfect Holding SA

About Kinarus

Kinarus AG is a Swiss clinical-stage biopharmaceutical company focused on bringing differentiated treatments to patients suffering from viral, respiratory, and ophthalmic diseases. Kinarus' differentiated therapeutic candidate, KIN001, has broad potential in numerous therapeutic areas.

For more information, please visit the company's website at www.kinarus.com.

Contact information

Alexander Bausch
CEO, Kinarus AG
Tel: +41 61 633 2971
alexander.bausch@kinarus.com

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Kinarus AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.


End of Media Release

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting